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Background-—Early age (<45 years) at menopause has been postulated to be associated with increased cardiovascular disease
risk; however, evidence of its relation with heart failure (HF) incidence is limited. We examined whether age at menopause is
associated inversely with HF incidence in the Atherosclerosis Risk In Communities (ARIC) study and summarized all existing data in
a meta-analysis.
Methods and Results-—In ARIC, data were obtained from 5629 postmenopausal women (mean age 56 years, 26% with bilateral
oophorectomy) without HF. During a median follow-up of 21.4 years, 965 incident HF events occurred. In a Cox regression model
adjusted for reproductive health and HF risk factors, the hazard ratios for incident HF across categories of age at menopause (<45,
45–49, 50–54, and ≥55 years) were 1.32, 1.17, 1.00 (referent), and 1.12, respectively. Compared with women with later onset of
menopause (aged ≥45 years), those with early menopause had elevated HF risk (hazard ratio 1.20, 95% CI 1.01–1.43). For the
meta-analysis, we searched Medline and Embase for articles published through December 2015 that prospectively evaluated age
at menopause and HF risk. Summarized estimates from the 3 included studies (3568 events) showed higher HF risk among women
with early menopause compared with those with later menopause (hazard ratio 1.33, 95% CI 1.15–1.53).
Conclusions-—These results provided evidence that early age at menopause is associated with a modestly greater risk of HF.
Identification of women with early menopause offers a window of opportunity to implement interventions that will improve overall
cardiovascular health during the postmenopausal years. ( J Am Heart Assoc. 2016;5:e003769 doi: 10.1161/
JAHA.116.003769)
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I t is controversial whether an association exists betweenmenopause and incident cardiovascular disease (CVD)
beyond age and cardiovascular risk factors, and the under-
lying mechanisms for such an association are poorly under-
stood. Numerous reports,1–3 with few exceptions,4 document
elevated risk of CVD in women with early natural or surgical
menopause (before age 45 years). Some have proposed that
the elevated CVD risk among women with early menopause
may be explained by estrogen deficiency,1,2 but emerging
evidence shows that women who undergo early menopause
tend to have adverse CVD risk factors long before
menopause.5
Despite heart failure (HF) accounting for 35% of all CVD
mortality among women,6 investigations of the relation
between early menopause and incident HF are limited. A
few short-term studies with small sample sizes suggest that
early onset of menopause is related to greater likelihood of
left ventricular (LV) dysfunction,7–9 which, in itself, raises the
risk of overt HF.10,11 Recent studies from the Swedish
Mammography Cohort12 and the Multi-Ethnic Study of
Atherosclerosis (MESA)13 reported 40% and 66% greater risk
of HF, respectively, in women with early versus later
menopause. The former study assessed a homogeneous
cohort of white, naturally menopausal women, and that limits
generalization of the findings to other races. The latter study
recorded few events during a short follow-up and failed to
distinguish between types of menopause, and that may have
led to misclassification because women with hysterectomy
and ovarian conservation were considered to have surgical
menopause. Further evidence is needed to clarify the
association of early menopause with HF.
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The aim of this study was to assess the association of age
at menopause with incident HF in a biracial cohort of
postmenopausal women enrolled in the Atherosclerosis Risk
In Communities (ARIC) study. We also pooled our results with
prior prospective studies in a meta-analysis to put our findings
in context and to provide a higher level of evidence.
Methods
Study Population
The ARIC study is a multicenter prospective cohort study that,
from 1987 to 1989, enrolled and examined 15 792 partici-
pants (8710 women) aged 45 to 64 years from 4 US
communities: Forsyth County, North Carolina; Jackson, Mis-
sissippi; suburbs of Minneapolis, Minnesota; and Washington
County, Maryland. Only black participants were recruited in
Jackson, whereas participants at the other field centers
reflected the underlying populations of mostly white residents
in the Minneapolis and Washington County sites and white
and black residents in Forsyth County. Since baseline, 4
follow-up examinations have been conducted: 1990 to 1992
(visit 2), 1993 to 1995 (visit 3), 1996 to 1998 (visit 4), and
2011 to 2013 (visit 5). Approximately 85% of surviving cohort
members or their proxies continue to respond to the
semiannual follow-up telephone calls. Details of the study
design and methods are described elsewhere.14 Local insti-
tutional review boards approved the ARIC protocol, and all
participants provided written informed consent. The present
analysis included all women who reached natural or surgical
menopause before ARIC visits 1 through 4, with the visit at
which a woman first reported being postmenopausal consid-
ered as baseline.
Measures
At each ARIC follow-up visit, standardized protocols were
used to collect information from participants about demo-
graphics, anthropometrics, lifestyle and behavioral factors,
medical history, cardiovascular risk factors, biomarkers, and
medication use. Women were also asked about history of
gynecological surgeries and their reproductive milestones:
age at menarche, parity, use of oral contraceptives, and
postmenopausal hormone therapy.
Consistent with previous ARIC reports, we excluded
women who underwent hysterectomy without bilateral
oophorectomy before age 55 years that was not preceded
by natural menopause, as age at menopause could not be
determined precisely for such women.15,16 At each ARIC visit,
the remaining women were considered to be postmenopausal
if they reported not having had a menstrual period within the
2 years before the visit. This definition is conservative and
ensured that perimenopausal women were not classified as
postmenopausal. Among postmenopausal women, those who
reported menstrual cessation due to bilateral oophorectomy
were classified as having surgical menopause, whereas those
who reported cessation of menstrual bleeding that was not
preceded by hysterectomy were classified as having natural
menopause. Age at menopause was defined as the age at last
menstrual period or bilateral oophorectomy. Consistent with
previous reports,2,13 women with onset of menopause before
age 45 years were classified as having early menopause.
Blood pressure was measured using a random-zero
sphygmomanometer with participants seated after 5 minutes
of rest. The average of the second and third consecutive
measurements was used for analysis. Body mass index (BMI)
was calculated by dividing weight in kilograms by height in
square meters. Waist circumference was measured at the
level of the umbilicus. Sports-related physical activity was
assessed by the Baecke questionnaire.17 Fasting plasma total
and high-density lipoprotein cholesterol were determined by
enzymatic methods. Estimated glomerular filtration rate was
calculated using the Chronic Kidney Disease Epidemiology
Collaboration formula, which incorporates both cystatin C and
creatinine.18 Diabetes mellitus was defined as a fasting blood
glucose level ≥7.0 mmol/L, nonfasting blood glucose
≥11.1 mmol/L, a self-reported physician diagnosis of dia-
betes mellitus, or current use of antidiabetic medication.
Prevalent HF, for exclusion, was defined by self-reported
use of HF medication or evidence of manifest HF by
Gothenburg criteria stage 319 for women who entered the
analytic sample at visit 1 or incident HF hospitalization prior
to the visit of entry for those who entered the analytic cohort
during follow-up. Prevalent coronary heart disease (CHD) was
ascertained from medical history or electrocardiographic
evidence of myocardial infarction or coronary revasculariza-
tion at visit 1 or an incident-adjudicated CHD event prior to
the visit of entry for those who entered the analytic cohort
during follow-up.
Incident HF Ascertainment
Incident HF occurring after visit 1 (1987–1989) up until
December 31, 2012, was defined as the first hospitalization
that included an International Classification of Diseases, 9th
Revision (ICD-9) discharge code of 428 (428.0–428.9) among
the primary or any secondary diagnosis or a death certificate
with an ICD-9 code of 428 or an ICD-10 code of I50 among
any of the listed or underlying causes of death.20
Statistical Analysis
Of the 8710 women enrolled from 1987 to 1989, 7294
women who reported having undergone menstrual cessation
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due to natural menopause, hysterectomy, or bilateral
oophorectomy during ARIC visits 1 to 4 were eligible for this
analysis. We excluded women who underwent hysterectomy
without bilateral oophorectomy before age 55 years that was
not preceded by natural menopause (n=897). In addition,
women with missing age at menopause (n=382) and prevalent
HF (n=355) and the few who reported races other than black
or white (n=31) were excluded, resulting in an analytic sample
of 5629 postmenopausal women.
Baseline data (at entry into the analytic cohort) were
expressed as means (SD) for continuous variables and as
percentages for categorical variables, stratified by age at
menopause (<45, 45–49, 50–54, and ≥55 years). The
Kaplan–Meier method was used to estimate cumulative
incidence of HF by categories of age at menopause, and the
log-rank test was used to test for differences between survival
curves. Cox proportional hazards regression was used to
estimate the hazard ratio (HR) of HF in relation to age at
menopause modeled in 2 ways: dichotomized as the presence
or absence of early menopause and as an ordinal categorical
variable, defined above. Because HF rates increase with
advancing biological age, attained age in years was used as
the time scale for all time-to-event analyses. Because of the
variable lengths of follow-up for participants, models that
accounted for left truncation of the data as a result of the
staggered entry were used. Five models with progressive
degrees of adjustment were used. Model 1 adjusted for age,
race, and ARIC field center. Model 2 also adjusted for
established HF risk factors. Model 3 further adjusted for
reproductive health measures. To assess whether the
observed association was mediated by CHD, we further
adjusted for interim CHD, defined as CHD that occurred
before HF, and modeled it as a time-varying covariate (model
4). Because of the long follow-up duration, we also modeled
longitudinally assessed BMI, systolic blood pressure, and the
use of antihypertensive medication and hormone therapy as
time-dependent covariates in model 5. Linear trends in HRs
across categories of age at menopause were tested by
modeling the median of each category as an ordinal variable
in the Cox models. A potential nonlinear relation between age
at menopause and incident HF was evaluated by using
restricted cubic splines. Wald chi-square tests were used to
formally test for multiplicative interactions of race, smoking
status, BMI, hormone therapy use, and type of menopause
with age at menopause in relation to incident HF. No
statistically significant 2-way interaction of age at menopause
with type of menopause (natural or surgical) was identified
(P=0.1819); therefore, we pooled the data. A 2-tailed P<0.05
was considered to be statistically significant. We tested and
confirmed the validity of the proportional hazards assumption
using interaction terms between categories of age at
menopause and the log of time, which in this case was
attained age. All analyses were performed using SAS software
version 9.4 (SAS Institute).
Meta-Analysis
Data Sources and Study Selection
We performed a systematic literature search in Medline and
Embase and evaluated all studies that assessed the associ-
ation of age at menopause with the risk of HF published up to
December 31, 2015, using the following keywords: age, early
menopause, menopause, postmenopause, bilateral oophorec-
tomy, and heart failure. This yielded 44 and 39 publications
from Medline and Embase, respectively. We also reviewed the
reference lists of retrieved articles. Studies were included (1)
if they had a cohort design, (2) if the main exposure of interest
was age at menopause or early menopause, (3) if the end
point of interest was incident HF, and (4) if they reported
adjusted relative risk or HR and 95% CI for the association of
age at menopause with HF incidence or mortality. Studies that
did not meet these criteria or that did not provide enough data
to allow calculation of the effect estimates were excluded. If
multiple reports were obtained from the same study popula-
tion, the most recent report was chosen. Two studies that met
the inclusion criteria and the present study were included in
the meta-analysis (Figure 1).
Data Extraction and Analysis
The following information was recorded for each study using a
standardized form: author, year of publication, location, study
design, sample size, study duration, number of events, and
number of women with early menopause. Effect estimates
from fully adjusted models were extracted. Standard errors
were calculated from the CIs provided. Summary estimates
across all studies were calculated using DerSimonian and
Laird’s random-effects method weighting individual study risk
estimates by the inverse of their variance.21 Heterogeneity
among studies was investigated using Cochran’s Q test and I2
with a P value of <0.10 to reject the null hypothesis that
estimates from the various studies are homogeneous. Publi-
cation bias was assessed using funnel plots, Begg’s adjusted
rank correlation,22 and Egger’ regression asymmetry tests23
at the P<0.10 level of significance. Analyses were conducted
using the R software (version 3.2.2; R Foundation for
Statistical Computing).24
Results
Of the 5629 postmenopausal women, 1468 (26.1%) reported
undergoing surgical menopause. Overall, 1611 women
(28.6%) reached menopause before age 45 years, with the
median age of menopause recorded as 49 and 44 years for
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women with natural and surgical menopause, respectively.
The distributions of characteristics of participants stratified by
categories of age at menopause are presented in Table 1. The
average age at menopause was higher for white than black
participants and showed positive associations with age,
education, systolic blood pressure, waist circumference, age
at menarche, and lipid-lowering medication use and negative
associations with parity, hormone therapy use, high-density
lipoprotein cholesterol, and estimated glomerular filtration
rate.
During a median follow-up of 21.4 years, 965 incident HF
events and 755 CHD events occurred. The incidence of HF
according to age at menopause of <45, 45 to 49, 50 to 54,
and ≥55 years was 10.7, 8.5, 7.3, and 10.7 events per 1000
person-years, respectively (Table 2); corresponding esti-
mates for CHD were 15.5, 13.8, 11.1, and 13.3 events
per 1000 person-years, respectively. In Kaplan–Meier cumu-
lative incidence analysis, a younger age at menopause was
significantly associated with higher incidence of HF (Fig-
ure 2). Compared with women who reached menopause at
age 50 to 54 years, the HRs for incident HF were 1.38,
1.16, and 1.08 for women who reached menopause at age
<45, 45 to 49, and ≥55 years, respectively (Table 2).
Additional adjustment for reproductive health factors and
interim CHD did not significantly alter the observed asso-
ciations with the HRs for incident HF, observed to be 1.32,
1.17, and 1.12 for women who reached menopause at age
<45, 45 to 49, and ≥55 years, respectively, compared with
women who reached menopause at age 50 to 54 years. A 1-
year increment in age at menopause was not significantly
inversely associated with the incidence of HF (HR 0.99, 95%
CI 0.98–1.00, P=0.16). No statistically significant (P>0.05)
2-way interactions of age at menopause with race, smoking
status, BMI, waist circumference, systolic blood pressure,
diabetes mellitus, hormone therapy use, or type of
menopause were identified.
Figure 1. Flowchart of study selection for the meta-analysis. CVD indicates cardiovascular disease.
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We also performed analyses based on the presence or
absence of early menopause (Table 2). Compared with
women with later onset of menopause (at age ≥45 years),
women who experienced early menopause (at age <45 years)
had a greater risk of HF after adjusting for education level,
smoking status, alcohol intake, BMI, waist circumference,
systolic blood pressure, antihypertensive medication use,
heart rate, diabetes status, estimated glomerular filtration
rate, and total and high-density lipoprotein cholesterol (HR
1.27, 95% CI 1.11–1.46; model 2). In the most fully adjusted
model (model 5), compared with women with later onset of
menopause, women with early menopause had a 20%
elevated risk of HF (HR 1.20, 95% CI 1.01–1.43). Further
adjustments for a history of cancer diagnosis did not
significantly influence the observed positive association
between early menopause and incident HF (data not shown).
The relation of age at menopause with incident HF was
reasonably linear (P=0.026), with results from restricted cubic
spline Cox regression analysis confirming this observation
(Figure 3).
Meta-Analysis
Table 3 summarizes the characteristics of the 3 prospective
studies included in the meta-analysis. In all 3 studies, age at
menopause was self-reported, whereas ICD code or clinical
Table 1. Characteristics of Participants According to Age at Menopause in the ARIC Study
Characteristics
Age at Menopause, y
Ptrend<45 45–49 50–54 ≥55
n 1611 1870 1795 353
Age, y 54.8 (5.6) 55.4 (4.6) 57.2 (3.5) 60.1 (2.7) 0.001
Race, black, % 37.5 28.1 20.5 28.0 0.001
Education (beyond high school), % 28.4 32.3 34.8 36.0 0.001
Smoking status, % 0.001
Former 22.9 25.8 24.1 25.3
Current 29.5 24.5 17.7 8.0
Alcohol intake, g/d 2.5 (7.4) 2.9 (6.9) 3.0 (7.6) 2.1 (5.3) 0.406
Heart rate, bpm 67.2 (10.6) 67.3 (10.0) 67.1 (9.7) 67.0 (9.9) 0.644
Systolic blood pressure, mm Hg 121.4 (19.8) 121.4 (20.1) 122.2 (19.0) 126.6 (19.9) 0.001
Hypertension medication use, % 33.0 31.4 29.3 36.5 0.360
Diabetes mellitus, % 13.8 12.4 10.6 14.8 0.108
Body mass index, kg/m2 28.0 (6.1) 27.9 (6.1) 28.0 (6.1) 28.7 (6.0) 0.064
Waist circumference, cm 96.2 (15.6) 96.2 (15.6) 96.2 (15.8) 98.8 (15.6) 0.005
Sports index 2.3 (0.7) 2.4 (0.8) 2.4 (0.8) 2.4 (0.7) 0.065
Parity, % 0.001
0 10.5 9.1 7.7 7.4
1 14.3 11.7 10.8 9.6
2 25.5 24.9 24.8 20.4
≥3 49.7 54.3 56.6 62.6
Age at menarche, y 12.8 (1.7) 12.9 (1.7) 13.0 (1.7) 13.1 (3.0) 0.002
Oral contraceptives (ever used), % 37.8 43.6 42.8 32.9 0.441
Hormone therapy (current use), % 25.8 23.6 17.8 13.9 0.001
Bilateral oophorectomy, % 48.9 22.5 11.8 13.6 0.001
HDL cholesterol, mmol/L 1.54 (0.5) 1.52 (0.5) 1.51 (0.4) 1.47 (0.4) 0.004
Total cholesterol, mmol/L 5.76 (1.1) 5.74 (1.1) 5.68 (1.1) 5.67 (1.1) 0.091
Lipid-lowering medication use, % 3.8 3.4 4.5 5.4 0.101
eGFR, mL/min/1.73 m2 103.8 (17.3) 101.9 (15.8) 98.8 (14.9) 94.7 (16.0) 0.001
Values are mean (SD) for continuous variables and percentages for categorical variables. ARIC indicates Atherosclerosis Risk In Communities; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein.
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adjudication (based on patient charts) was used for diagnos-
ing HF incidence. The Swedish Mammography Cohort12 and
the MESA13 were the 2 other prospective studies identified
that evaluated the association of age at menopause with the
incidence of HF, and those studies respectively reported 40%
and 66% greater risk of HF in women with early versus later
onset of menopause. In total, including the present study,
3568 HF events were included in the meta-analysis. Overall, a
1-year increment in age at menopause was minimally
inversely associated with the risk of HF (HR 0.98, 95% CI
0.97–0.995, P=0.009). Compared with women with later
onset of menopause, women who experienced early meno-
pause (at age <45 years) had a significantly greater risk of HF
(HR 1.33, 95% CI 1.15–1.53) (Figure 4). We did not observe
evidence of heterogeneity of the results (Q=2.60, I2=22.9%,
P=0.27). Finally, we were unable to detect the presence of
Table 2. Hazard Ratios and 95% CIs for the Association of Age at Menopause With Incident HF in the ARIC Study, 1987 to 2012
Events n Incidence Rate* Model 1 Model 2 Model 3 Model 4 Model 5
Age at menopause, y
<45 336 1611 10.7 (9.6–11.9) 1.47 (1.25–1.74) 1.38 (1.16–1.63) 1.35 (1.11–1.63) 1.32 (1.09–1.60) 1.39 (1.12–1.74)
45–49 313 1870 8.5 (7.6–9.5) 1.22 (1.03–1.44) 1.16 (0.97–1.37) 1.15 (0.96–1.38) 1.17 (0.98–1.40) 1.26 (1.02–1.56)
50–54 250 1795 7.3 (6.5–8.3) 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent)
≥55 66 353 10.7 (8.4–13.6) 1.16 (0.88–1.52) 1.08 (0.82–1.43 1.14 (0.86–1.51) 1.12 (0.85–1.49) 1.26 (0.88–1.81)
Ptrend 0.001 0.001 0.007 0.012 0.019
Early menopause
Age ≥45 y 629 4018 8.2 (7.6–8.9) 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent)
Age <45 y 336 1611 10.7 (9.6–11.9) 1.32 (1.15–1.51) 1.27 (1.11–1.46) 1.23 (1.06–1.44) 1.21 (1.03–1.41) 1.20 (1.01–1.43)
ARIC indicates Atherosclerosis Risk In Communities; HF indicates heart failure.
Model 1: Hazard ratio with 95% CI from Cox proportional hazards model adjusted for age and race by field center. Model 2: Model 1 was additionally adjusted for education level (less than
high school, high school, beyond high school), smoking status (never, former, current), alcohol intake (continuous), body mass index (continuous), waist circumference (continuous),
systolic blood pressure (continuous), antihypertensive medication use (yes or no), heart rate (continuous), diabetes mellitus status (yes or no), estimated glomerular filtration rate
(continuous), total and high-density lipoprotein cholesterol (continuous). Model 3: Model 2 was additionally adjusted for age at menarche (continuous), oral contraceptive use (ever, never),
parity, hormone therapy use (never, former, current), and type of menopause (natural, surgical). Model 4: Model 3 was additionally adjusted for coronary heart disease occurring before
heart failure incidence as a time-varying covariate. Model 5: Model 4 was additionally adjusted for time-varying covariates of systolic blood pressure, body mass index, and use of
antihypertensive medication and hormone therapy during the 25 years of follow-up.
*Unadjusted incidence rate per 1000 person-years with 95% CI.
Figure 2. Kaplan–Meier cumulative incidence estimates of HF
according to age at menopause, ARIC, 1987 to 2012. Log-rank
test P=0.001. ARIC indicates Atherosclerosis Risk In Commu-
nities; HF, heart failure.
Figure 3. Restricted cubic spline depicting relationship
between age at menopause and incident HF adjusted for age,
race, and center. Reference value was 51 years, the average for
age at natural menopause in developed countries. The 95% CIs
are gray. Knots set at fifth, 35th, 65th, and 95th percentiles of
age at menopause. HF indicates heart failure.
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publication bias in our analyses (Begg test P=0.60, Egger’s
bias=1.23, P=0.67), possibly because of the few number of
studies included in the quantitative review.25
Discussion
Results from this large prospective observational cohort of
white and black women enrolled in the ARIC study with a
median of 21 years of follow-up showed a generally inverse
association between age at menopause and incident HF;
however, the modestly elevated risk of HF was mainly limited
to women who reached menopause before age 45 years (HR
1.20). This observation was confirmed by a meta-analysis
pooling our data with 2 other prospective studies12,13 that
found women with early menopause to have elevated HF risk
(HR 1.33). It is worth noting that, similar to other investiga-
tions,12 we observed a higher incidence of HF among women
who reached menopause after age 55 years compared with
women who reached menopause at 50 to 54 years, but this
result did not attain statistical significance in either crude or
multivariable adjusted models. HF affects about 2.4 million
American women,6 and the prevalence has been projected to
increase by 46% by the end of 2030.26 With 10% all women
experiencing natural menopause before age 45 years27 and
two-thirds of all surgical menopause occurring before age
50 years,28 identification of women with early menopause as
a population at high risk of HF provides a window of
opportunity for intervention to prevent the onset of HF.
Menopause is characterized by physiological changes that
influence several organs and systems, with the cardiovascular
system among the most predominantly affected.8 Although
early age at menopause is widely believed to be associated
with greater risk for CVD events, its relation with incident HF
has not been investigated in detail. Previous small studies
reported that, compared with premenopausal women, post-
menopausal women had more LV systolic and diastolic
dysfunction,7–9,29 an important predictor of overt HF.10,11 A
study among 72 postmenopausal women and 71 age-
matched premenopausal women observed that menopause
negatively affected myocardial velocities and myocardial
performance.8 Similarly, other case–control studies reported
that, compared with premenopausal women, postmenopausal
women had higher relative wall thickness and concentric LV
geometric remodeling independent of high blood pressure30
and lower peak early diastolic velocity E wave and mitral E/A
ratio, indicative of impaired LV diastolic filling.31 In a study of
50 postmenopausal women who reported ages at menopause
ranging from 29 to 55 years, Kaur et al9 observed significant
impairment in LV systolic function among women who
reached menopause before age 40 years compared with
those with onset of menopause at age ≥50 years.
Emerging epidemiological evidence suggests that early
menopause is positively associated with incident HF. After
following 22 256 postmenopausal women enrolled in the
Swedish Mammography Cohort for an average of 13 years,
Rahman et al12 observed a 40% elevated risk of HF among
women who experienced early natural menopause (at age 40–
45 years) compared with those who reached menopause at
age 50 to 54 years. Smoking was found to modify the
association by augmenting HF risk beyond expectations
among women with onset of menopause between ages 46
and 49 years. Likewise, results from 2947 postmenopausal
women enrolled in MESA13 with a median follow-up of
8.5 years showed a 66% greater risk of HF in women with
early menopause (at age <45 years) compared with women
with onset of menopause at age ≥45 years. Consistent with
these results, we also observed a 30% greater risk of HF
among women with onset of menopause before age 45 years
compared with those who reached menopause at age 50 to
54 years. This elevated HF risk among women with early
Table 3. Characteristics of Studies That Assessed the Relation of Age at Menopause With Incident HF
Author Study Location Design Sample Events
Early
Menopause, n Follow-up, y
Ebong et al (2014)13 Multi-Ethnic Study of Atherosclerosis United States Prospective cohort 2947 71 730 8.5 (median)
Rahman et al (2015)12 Swedish Mammography Cohort Sweden Prospective cohort 22 256 2532 1571 13 (mean)
Appiah et al (current study) Atherosclerosis Risk In Communities United States Prospective cohort 5629 965 1611 21.4 (median)
HF indicates heart failure.
Figure 4. Forest plot of hazard ratios and 95% CIs for the
association of early menopause (at age <45 years) versus later
menopause (at age ≥45 years) with incident HF. Appiah et al is
the current study. HF indicates heart failure.
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menopause was reduced to 19% when we compared them
with all women with onset of menopause at age ≥45 years
and adjusted for other HF risk factors. It is well known that
smoking decreases the age of natural menopause by 1 to
2 years32 and by as much as 9 years in women with certain
genetic variants.33 In contrast to the Swedish Mammography
Cohort, the present study and MESA did not identify any
interaction of early menopause with smoking status, and we
did not observe race, hormone therapy, general adiposity, or
type of menopause modifying the association of early
menopause with incident HF.
The underlying mechanisms by which early menopause may
influence HF risk remain elusive. Because early menopause
leads to reduced exposure to endogenous estrogens, it has
been postulated that such women experience less lifetime
cardioprotective effect of ovarian estrogen. This argument was
first observed among premenopausal women with bilateral
oophorectomy, among which those who used exogenous
hormones had lower incidence of CVD events compared with
those without hormone therapy use.34 Estrogen deficiency
after menopause predisposes women to adverse levels of risk
factors for HF,35 and evidence from animal models suggests
that reduced estrogen levels may directly or indirectly
contribute to diastolic dysfunction and hypertensive heart
diseases in postmenopausal women. Specifically, the loss of
ovarian estrogens leads to chronic activation of the renin–
angiotensin–aldosterone system and the nitric oxide synthase
system as well as other related intracellular signaling
pathways, in part via the membrane G protein–coupled
receptor 30.35,36 This can result in endothelial dysfunction,
inflammation, and immune dysfunction, which may lead to
collagen synthesis, LV remodeling, and diastolic dysfunc-
tion,35–37 the latter being a major cause of HF among
women.38 Despite these reported cardioprotective roles of
hormone therapy in experimental studies, there are contrast-
ing reports about the influence of hormone therapy for the
prevention of CVD end points among postmenopausal women.
On the one hand, some controlled primary prevention trials
show slower progression of subclinical CVD39,40 and lower risk
of CVD mortality41 among postmenopausal women on
hormone therapy compared with those on placebo. On the
other hand, other randomized trials have observed no benefits
of hormone therapy in the primary42,43 or secondary44–46
prevention of CVD end points in postmenopausal women.
Although a few trials among recently menopausal women
show slower progressions of carotid artery intima–media
thickness in women taking estradiol,47 others show no effect
of estradiol or other hormone therapies on vascular endothelial
function,48 carotid artery intima–media thickness,49 or coro-
nary artery calcium and total stenosis.47 These equivocal
results cast doubt about a cardioprotective role for estrogen in
CVD development among postmenopausal women.
It is possible that other processes besides ovarian
estrogen deficiency contribute to both early menopause and
HF or CVD incidence, and thus the observed association may
not be causal. Accumulating evidence suggests that CVD risk
factors (and latent CVD) may influence the timing of
menopause. Results from the Framingham Heart Study cohort
showed that greater levels of cholesterol, relative weight, and
blood pressure were each associated with early onset of
natural menopause, independent of smoking.5 In contrast, the
Coronary Artery Risk Development in Young Adults study,
which followed 1045 premenopausal women with an average
age of 26 years at baseline for 25 years, observed that
trajectories of total cholesterol, triglycerides, BMI, and
systolic blood pressure were elevated in women who had
earlier onset of both natural and surgical menopause.50 Other
studies have also identified genetic predictors of age at
menopause33 and early menopause.51 In a follow-up of the
National Health and National Examination Survey, the ele-
vated risk of CVD mortality in women with surgical
menopause before age 45 years was limited to those who
reported a family history of CHD, suggesting that the relation
of surgical menopause and CVD may be explained by
susceptibility genes that increase the risk of both out-
comes.52 Analogously, the elevated incidence of HF among
women with early menopause observed in this and other
studies may reflect residual confounding of unmeasured
variables.
The strengths of this study include the use of a large
population-based biracial sample, extensive assessment of HF
risk factors, conservative definition of postmenopausal status,
and 25 years of follow-up. Potential limitations of this study
warrant consideration. First, age at menopause was self-
reported and may be subject to recall error. The precision of
recollecting age at menopause appears to decrease as time
since menopause increases.53 This may contribute to dilution
of the relative hazard estimates, as women who had early
menopause may subsequently report an older age at
menopause. A woman’s accuracy in recalling age at bilateral
oophorectomy seems to surpass recall of age at natural
menopause.54 Second, HF events were ascertained using ICD
codes from hospital discharge and death certificates, which
may not capture events occurring in outpatients, although
most outpatient HF patients are eventually hospitalized.55 In
ARIC, the validity of ICD codes for identifying HF events is
high.56 Finally, information on subtypes of HF at diagnosis
was not available.
In conclusion, our findings demonstrate a modest associ-
ation between early age at natural or surgical menopause and
greater incidence of HF, which is consistent with previous
reports. Owing to the burden of HF in women and the
projected increase in HF prevalence, research to establish
causality and to understand the mechanisms underlying early
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onset of menopause and how it may contribute to HF are
needed. Such information might contribute to improving the
long-term cardiovascular health of women who experience
early menopause.
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